PMGC Holdings (ELAB) Revenue (2022 - 2026)
PMGC Holdings (ELAB) posted Revenue of $681994.0 for Q1 2026, up 124.24% sequentially from $304136.0 in Q4 2025, and up 347.56% YoY from $152381.0 in Q1 2025.
PMGC Holdings (ELAB) Revenue (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Revenue for 5 years, with the latest figure at $681994.0 in Q1 2026.
- Quarterly Revenue rose 347.56% year-over-year to $681994.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 36.56% YoY) and the FY2025 annual result came in at $590084.0, down 76.08% from the prior year.
- Revenue grew to $681994.0 in Q1 2026 per ELAB's latest filing, from $304136.0 in the prior quarter.
- Over five years, Revenue peaked at $432.1 million in Q3 2022 and troughed at -$626.6 million in Q4 2022.
- A 5-year average of -$13.5 million and a median of $541065.5 in 2023 frame the typical range for Revenue.
- The sharpest annual moves came in 2023 and 2026: Revenue tumbled 99.87% in 2023, then soared 347.56% in 2026.
- Over 5 years, Revenue stood at -$626.6 million in 2022, then jumped by 100.11% to $698591.0 in 2023, then increased by 3.03% to $719728.0 in 2024, then plunged by 57.74% to $304136.0 in 2025, then jumped by 124.24% to $681994.0 in 2026.
- According to Business Quant data, Revenue over the past three periods registered $681994.0, $304136.0, and $285948.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | PMGC Holdings | 3.01 Mn | -15.78 Mn | 385,691.00 | 1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 681,994.00 |
| Dec 31, 2025 | 304,136.00 |
| Sep 30, 2025 | 285,948.00 |
| Mar 31, 2025 | 152,381.00 |
| Dec 31, 2024 | 719,728.00 |
| Sep 30, 2024 | 527,477.00 |
| Jun 30, 2024 | 605,530.00 |
| Mar 31, 2024 | 614,563.00 |
| Dec 31, 2023 | 698,591.00 |
| Sep 30, 2023 | 554,654.00 |
| Jun 30, 2023 | 316,530.00 |
| Mar 31, 2023 | 142,820.00 |
| Dec 31, 2022 | -626.61 Mn |
| Sep 30, 2022 | 432.12 Mn |